# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Chi Fong maintains Roivant Sciences (NASDAQ:ROIV) with a Neutral and raises the price target from ...
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...
Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $...
Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...
Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.
mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD tr...
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...